A Study of BGM0504 in Participants With Obesity
NCT06911203 on ClinicalTrials.gov · last registry update 2026-10-13
Finished 14 January 2026, after enrolling 96 people. Primary outcome, as filed: Change From Baseline in Body Weight. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 3 times since then.
- Status
- COMPLETED
- Phase
- P2
- Drug
- tirzepatideMounjaro, Zepbound
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 96
- Started
- 2025-04-09
- Primary completion
- 2026-01-14 actual
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-10-13 | Status changed | RECRUITING → COMPLETED |
| 2026-10-13 | Reporting date moved | 2026-01-11 → 2026-01-14 |
| 2026-10-13 | Enrollment changed | 90 → 96 (+6) participants |
Primary outcome
Change From Baseline in Body Weight
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.